Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
Targeted drug delivery strategies for precision medicines
Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …
Precision medicine is propelled by technologies that enable molecular profiling, genomic …
[HTML][HTML] Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer
L Yang, HJ Xie, YY Li, X Wang… - Oncology …, 2022 - build.spandidos-publications.com
Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
State-of-the-art strategies for targeting the DNA damage response in cancer
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …
damage response (DDR) and/or increased replication stress. These alterations promote the …
KRAS mutation in pancreatic cancer
J Luo - Seminars in oncology, 2021 - Elsevier
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …
Emerging strategies to target RAS signaling in human cancer therapy
K Chen, Y Zhang, L Qian, P Wang - Journal of hematology & oncology, 2021 - Springer
Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
C Nevala-Plagemann, M Hidalgo… - Nature reviews Clinical …, 2020 - nature.com
Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC)
have lagged behind advances made in the treatment of many other malignancies over the …
have lagged behind advances made in the treatment of many other malignancies over the …
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …
Therapeutic strategies to target RAS-mutant cancers
MB Ryan, RB Corcoran - Nature reviews Clinical oncology, 2018 - nature.com
RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
A mounting body of evidence now indicates that PARP inhibitors have the potential to be
used as a foundation for both monotherapy and combination strategies across a wide …
used as a foundation for both monotherapy and combination strategies across a wide …